Trial
NCT04485104
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Jazz Pharmaceuticals
Collaborators
Jazz Pharmaceuticals Research UK Limited
Condition
Seizure in Participants With Tuberous Sclerosis Complex
Intervention
GWP42003-P
Why stopped
The study was terminated by the Sponsor due to low patient enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-31